Wednesday, May 25, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

mRNA boosters enhance neutralization of SARS-CoV-2 BA.1, BA.2 and BA.3

by Medical Finance
in Coronavirus
Study: SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. Image Credit: Steve Heap / Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

A study recently published in the journal Cell Host & Microbe has described that all three sublineages of the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit similar host cell entry efficiency and are neutralized equally by antibodies generated in response to coronavirus disease 2019 (COVID-19) booster vaccination. However, these sublineages exhibit different susceptibility to therapeutic antibody-mediated neutralization.

Study: SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. Image Credit: Steve Heap / ShutterstockStudy: SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. Image Credit: Steve Heap / Shutterstock

Background

The omicron variant of SARS-CoV-2 was first detected in South Africa on November 24, 2021. Soon after its emergence, the variant became dominant in many countries across the world. The presence of more than 25 mutations in the spike protein is believed to be responsible for its high transmission and immune evasion abilities.

The omicron variant has five main sublineages, namely BA.1, BA.2, BA.3, and more recently BA.4 and BA.5. The amino acid sequences in the N-terminal domain (NTD) and receptor-binding domain (RBD) of the spike proteins differ significantly between these sublineages. Studies have shown that the BA.2 sublineage has comparatively higher transmissibility than BA.1 and BA.3 sublineages and is currently circulating predominantly in many countries, including Denmark and the UK.

In the current study, the scientists have compared the host cell entry efficiency of three omicron sublineages, BA.1, BA.2, and BA.3. In addition, they have assessed the susceptibility of these sublineages to COVID-19 vaccine- and therapeutic antibody-mediated neutralization.

Host cell entry efficiency of omicron sublineages

The analysis of spike protein sequences revealed that the BA.2 sublineage differs significantly from the other two sublineages. While the amino acid residues 24-26 are missing from the BA.2 spike NTD, these residues are present in the NTDs of BA.1 and BA.3 sublineages. In contrast, the residues 69-70 and 143-145 are absent in the BA.1 and BA.3 spikes but are present in the BA.2 spike. Besides these variations, all three sublineages contain specific and unique spike mutations.

The in vitro experiments conducted using sublineage-specific spike protein-harboring pseudovirus particles revealed that the BA.1, BA.2, and BA.3 sublineages enter human cells with higher efficiency than the ancestor SARS-CoV-2 variant (B.1). However, there was no significant difference in cell entry efficiency between the sublineages.

Regarding mode of entry, all sublineages were found to enter host cells via angiotensin-converting enzyme 2 (ACE2)-mediated pathway, similar to the ancestor virus. Specifically, the spike proteins of omicron sublineages and ancestor virus showed similar efficiency in binding ACE2. Except for the ancestor virus, all omicron sublineages showed efficient binding to mouse, bat, and human ACE2 for cell entry.

The fusion between infected and uninfected cells via spike protein leads to syncytia formation, which is believed to be responsible for COVID-19 progression. The cell-cell fusion assays conducted in the study showed that the BA.1 sublineage had a reduced ability to form syncytia compared to the SARS-CoV-2 delta variant. Moreover, no significant difference in syncytia formation was observed between omicron sublineages.

Susceptibility of omicron sublineages to antibody-mediated neutralization

A total of eight monoclonal antibodies that are used for COVID-19 therapy were tested against omicron sublineages. The findings revealed that seven out of eight tested antibodies fail to effectively neutralize the BA.2 sublineage. The only antibody that effectively neutralized BA.2 was Cilgavimab.

A high efficacy neutralization of BA.1 was carried out by Sotrovimab. Similarly, BA.3 was effectively neutralized by both Cilgavimab and Sotrovimab. However, the neutralizing efficiency of tested antibodies against omicron sublineages was lower than that against the ancestor virus.

The COVID-19 vaccine efficacy against omicron sublineages was tested using serum samples collected from vaccinated participants. Specifically, the efficacy of a three-dose regimen of homologous mRNA vaccine (Pfizer) and the heterologous mRNA and adenoviral vector vaccine (AstraZeneca) was tested.

The findings revealed that all tested vaccination regimens effectively and equivalently neutralized all three omicron variant sublineages. However, the neutralizing efficiency was 4 to 6-fold lower than that observed against the ancestor virus.

Study significance

The study highlights that omicron sublineages have comparable efficacy in entering the host cell via ACE2 receptor. The antibodies induced by a three-dose regimen of homologous or heterologous COVID-19 vaccination (two prime and one booster vaccination) can neutralize all the sublineages with equivalent efficiency. However, the majority of monoclonal therapeutic antibodies against COVID-19 fail to neutralize the most transmissible BA.2 sublineage of the omicron variant. Based on the findings, the scientists suggest that Cilgavimab might be used to treat patients with BA.2 infections.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Post-Acute COVID-19 Syndrome (PACS) in Adults. Image Credit: Josie Elias/Shutterstock

Study explores long COVID in adults

by Medical Finance
May 24, 2022
0

A recent study published by Public Health Ontario reviewed post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS) in the adult population. Study:...

Study: Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective. Image Credit: CROCOTHERY/Shutterstock

Bacteria-mediated oral delivery of viral replicon-based mRNA vaccines

by Medical Finance
May 25, 2022
0

In a recently published article in Frontiers in Immunology, scientists have discussed the possibilities of developing oral replicon-based mRNA vaccines...

Small cluster of neurons in the brain stem found to coordinate vocalization with breathing

Over a third vaccinated-but-unboosted adults have reservations about vaccinating children

by Medical Finance
May 24, 2022
0

While the vast majority of U.S. adults who are fully vaccinated and boosted against Covid-19 would be likely to recommend...

Study: Would New SARS-CoV-2 Variants Change the War against COVID-19? Image Credit: eamesBot/Shutterstock

reinfection, vaccines, and herd immunity

by Medical Finance
May 24, 2022
0

Different technological platforms are being used to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative pathogen...

Study: Promising efficacy of following a third dose of mRNA SARS-CoV-2 vaccination in patients treated with anti-CD20 antibody who failed 2-dose vaccination. Image Credit: No-Mad/Shutterstock

Evaluating a third SARS-CoV-2 mRNA vaccine in anti-CD20-treated patients

by Medical Finance
May 24, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers assessed the efficacy of a third dose of coronavirus...

Study: Understanding Definitions and Reporting of Deaths Attributed to COVID-19 in the UK – Evidence from FOI Requests. Image Credit: Terelyuk/Shutterstock

Exploring definitions related to COVID-19 infection and deaths

by Medical Finance
May 24, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers assessed the definitions and reports of coronavirus disease 2019...

Next Post
Dog brains can detect speech and show different activity patterns to many languages

Researchers analyze the development and genetic profile of brain's immune cells

Study: Reporting Rates for VAERS Death Reports Following COVID-19 Vaccination, December 14, 2020-November 17, 2021. Image Credit: Anze Furlan / Shutterstock

CDC/FDA reports on VAERS - no association between vaccines and increased mortality

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Pandemic 620x480
    COVID-19 pandemic has widened gender inequities in health
  • bacteria Sebastian Kaulitzki 46826fb7971649bfaca04a9b4cef3309 620x480
    Study shows that key parts of human immunity are shared in bacteria
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply